Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center
Key Highlights
- ➤ERNA-101 selected for Flash Talk at Nature Conferences’ cancer therapeutics meeting
- ➤ERNA-101 drove significant tumor regression and enhanced survival in ovarian cancer models
- ➤PD-1 combination achieved complete tumor control and durable majority-animal responses
- ➤Biodistribution studies localized ERNA-101 to tumors without detectable signal in evaluated organs
- ➤Ernexa plans Q4 2026 IND submission and Q4 2027 clinical data for ERNA-101
Expert Statements
Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics
“Selection for presentation at a Nature Conferences meeting co-hosted by MD Anderson Cancer Center highlights the strength of our preclinical findings for ERNA-101, and we look forward to engaging with researchers and oncology leaders focused on advancing the next generation of cancer therapies.”
Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics
“Our data demonstrate the potential of our allogeneic, off-the-shelf approach to deliver immune-activating cytokines to the tumor microenvironment, recruit key immune cells and enhance the activity of checkpoint blockade.”
Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics
“We believe these findings provide a strong scientific foundation for advancing ERNA-101 toward the clinic and investigating its potential to address the significant unmet need in ovarian cancer.”
CAMBRIDGE, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced that new preclinical data from its lead oncology program, ERNA-101, have been selected for a Flash Talk presentation at the Next-Generation Cancer Therapeutics meeting, co-hosted by Nature Conferences and The University of Texas MD Anderson Cancer Center.
The meeting will take place October 6–8, 2026, on MD Anderson’s campus in Houston, Texas. The presentation will highlight ERNA-101’s potential to address a fundamental challenge in ovarian cancer: the immunosuppressive tumor microenvironment that can limit effective antitumor immune responses. In preclinical models of high-grade serous ovarian cancer, ERNA-101 promoted immune cell recruitment and was associated with significant tumor regression and enhanced survival. When combined with PD-1 checkpoint blockade, ERNA-101 demonstrated enhanced antitumor activity, including complete tumor control and durable responses in the majority of treated animals.
Get started
Create a free account to read the full story.